Drugs / SentoClone®
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00991250 | Oct 2009 → Sep 2011 | melanoma | SentoClone AB | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SentoClone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00991250 ↗ |
| Modality | Cell therapy | “SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient” NCT00991250 ↗ |
| Route | Intravenous | “returned to the patient intravenously as an autologous cell transfusion” NCT00991250 ↗ |